Biogen Inc. (0R1B.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Biogen Inc.
Address
225 Binney St
Cambridge, MA
United States of America (the)
Phone
17814642000
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
7605
First IPO Date
September 17, 1991
Key Executives
| Name | Title | Pay | Year Born |
| Christopher A. Viehbacher | President, Chief Executive Officer & Director | 5.28M | 1961 |
| Rachid Izzar | Executive Vice President and Head of Global Product Strategy & Commercialization | 1.27M | 1975 |
| Ginger Gregory | Executive Vice President & Chief Human Resources Officer | 1.59M | 1968 |
| Robin C. Kramer | Executive Vice President & Chief Financial Officer | 1.63M | 1966 |
| Priya Singhal | Executive Vice President & Head of Development | 2.01M | 1968 |
| Nicole Murphy | Executive Vice President and Head of Pharmaceutical Operations & Technology | 2.01M | 1973 |
| Susan H. Alexander | Executive Vice President & Chief Legal Officer | 2.25M | 1957 |
| Wolfram Schmidt | President & Head of Europe | 0 | N/A |
| Sean Godbout | VP, Chief Accounting Officer & Global Corporate Controller | 0 | 1974 |
| Alisha A. Alaimo | President & Head of North America | 0 | N/A |
| Guy Hadari | Chief Information Officer | 0 | N/A |
| Adam Keeney | Executive Vice President & Head of Corporate Development | 0 | 1977 |
| Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | 0 | N/A |
| Tim Power | Head of Investor Relations | 0 | N/A |
| Fraser Hall | President & Head of Intercontinental Region | 0 | N/A |
Description
Biogen Inc. is a biopharmaceutical firm dedicated to the discovery, advancement, and provision of treatments for conditions affecting the nervous system. Headquartered in Cambridge, Massachusetts, the company employs 7,800 full-time staff. Its primary focus involves the research, development, production, and distribution of therapies targeting a range of severe neurological, rare, and autoimmune disorders. Among its commercialized pharmaceutical offerings are medications such as TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA, all prescribed for multiple sclerosis (MS). Additionally, Biogen provides FUMADERM for severe plaque psoriasis and SPINRAZA for individuals with spinal muscular atrophy (SMA). Biogen also maintains a strategic alliance with Genentech, Inc., a member of the Roche Group. This partnership covers products like RITUXAN, utilized for conditions such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL), and GAZYVA, indicated for CLL and follicular lymphoma, alongside other anti-CD20-based treatments. The company's development pipeline features numerous experimental therapies, including OCREVUS, Biosimilar adalimumab, Aducanumab, E2609, BIIB074, BAN2401, Opicinumab, CIRARA, BIIB061, BIIB054, BIIB067, and BIIB068.
